AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22241513 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg) once daily for 2 weeks, followed by weight-adjusted doses for 4 weeks.
Number of subjects: 98
Study 22241513 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks after initial treatment.
Number of subjects: 98
Study 22241513 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg) for infants with symptomatic GERD.
Number of subjects: 98
Study 22241513 — intervention group
Group type: COMPARATOR
Intervention: Placebo for infants with symptomatic GERD.
Number of subjects: 98
Study 20090377 — intervention group
Group type: COMPARATOR
Intervention: Individualized parenteral nutrition (IPN)
Number of subjects: 107
Study 20090377 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized parenteral nutrition (SPN)
Number of subjects: 107
Study 19045968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study 19045968 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exposure plus response prevention (ERP)
Number of subjects: 0
Study 19045968 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive therapy (CT)
Number of subjects: 0
Study 19045968 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus response prevention (ERP)
Number of subjects: 0
Study 15911666 — intervention group
Group type: EXPERIMENTAL
Intervention: Transosseous repair with No. 3 Ethibond using modified Mason‐Allen sutures
Number of subjects: 100
Study 15911666 — intervention group
Group type: COMPARATOR
Intervention: Transosseous repair with 1.0 mm polydioxanone cord using modified Kessler sutures
Number of subjects: 100
Study 12771265 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 8
Study 12731753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir intranasal spray (6.4 mg)
Number of subjects: 47
Study 12731753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 8730002 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 764
Study 8730002 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic care
Number of subjects: 764
Study 8730002 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged to GP care
Number of subjects: 764
Study 1656040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg once daily)
Number of subjects: 360
Study 1656040 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100-200 mg once daily)
Number of subjects: 360
Study 1656040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 360
Study 1656040 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 360
Study 31577749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose misoprostol combined with mifepristone
Number of subjects: 0
Study 31577749 — intervention group
Group type: COMPARATOR
Intervention: Rivanol combined with mifepristone
Number of subjects: 0
Study 30172036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (8–12 behavioral-education sessions over 12 weeks)
Number of subjects: 48
Study 30172036 — intervention group
Group type: COMPARATOR
Intervention: Control group (dialysis education without incorporated CB techniques)
Number of subjects: 48
Study 27411564 — intervention group
Group type: COMPARATOR
Intervention: UNIMMAP containing 60 mg/d iron (reference arm)
Number of subjects: 462
Study 27411564 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP containing 60 mg/d iron based on weekly hepcidin screening
Number of subjects: 462
Study 27411564 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP containing 30 mg/d iron for 12 weeks
Number of subjects: 462
Study 27411564 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 462
Study 24695898 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein-calorie supplementation during pregnancy and early childhood (1987-1990)
Number of subjects: 1446
Study 24695898 — intervention group
Group type: EXPERIMENTAL
Intervention: Current lean mass and weight-bearing physical activity
Number of subjects: 1446
Study 24695898 — intervention group
Group type: EXPERIMENTAL
Intervention: Current serum 25-hydroxyvitamin D and dietary intake of calcium, protein, or calories
Number of subjects: 1446
Study 22283356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone application for recording symptoms and physical activity exertion, evaluated with the System Usability Scale (SUS) questionnaire 2 months after the intervention.
Number of subjects: 158
Study 22283356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone diaries for daily symptom reporting via morning and evening questionnaires.
Number of subjects: 158
Study 22283356 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 158
Study 20367330 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw fish-free diet for 6 months
Number of subjects: 87
Study 20367330 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test for food allergens including Ani s1
Number of subjects: 87
Study 19186858 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive
Number of subjects: 43
Study 19186858 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid
Number of subjects: 43
Study 15946614 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation programme
Number of subjects: 476
Study 15946614 — intervention group
Group type: COMPARATOR
Intervention: Habitual monitoring
Number of subjects: 476
Study 12885800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chromic phosphate suspension (32P) therapy (15 mCi)
Number of subjects: 202
Study 12885800 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (NFT)
Number of subjects: 202
Study 10776506 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of antiovarian antibody in POF patients
Number of subjects: 18
Study 8933855 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine premedication (0.01 mg/kg intramuscularly 30 min before procedure)
Number of subjects: 28
Study 8933855 — intervention group
Group type: COMPARATOR
Intervention: No atropine premedication (control group)
Number of subjects: 28
Study 1896817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (140 mg/day)
Number of subjects: 10
Study 1896817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (200 mg/day)
Number of subjects: 10
Study 1896817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1896817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (both doses)
Number of subjects: 10
Study 7160549 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 7160549 — intervention group
Group type: COMPARATOR
Intervention: Control (Acarbose without Metronidazole)
Number of subjects: 0
Study 30897454 — intervention group
Group type: EXPERIMENTAL
Intervention: Active calf muscle electrical stimulation (ES)
Number of subjects: 16
Study 30897454 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation
Number of subjects: 16
Study 26817648 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention with telephone coaching
Number of subjects: 63
Study 26817648 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus telephone calls
Number of subjects: 63
Study 26817648 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management exercise programme (adherence > 75%)
Number of subjects: 63
Study 26817648 — intervention group
Group type: COMPARATOR
Intervention: Physical activity, functional ability and health-related quality of life measures
Number of subjects: 63
Study 26104223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical infiltration with botulinum toxin
Number of subjects: 66
Study 26104223 — intervention group
Group type: EXPERIMENTAL
Intervention: Group problem-solving therapy
Number of subjects: 66
Study 26104223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 66
Study 24676798 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes
Number of subjects: 272
Study 24676798 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy weight control behaviors (UWCBs)
Number of subjects: 272
Study 24676798 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes and weight status
Number of subjects: 272
Study 24676798 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes and UWCBs
Number of subjects: 272
Study 21846056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydazepam and succinic acid
Number of subjects: 0
Study 21846056 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological correction
Number of subjects: 0
Study 19398471 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision support
Number of subjects: 2787
Study 17078084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 64
Study 17078084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 64
Study 16375656 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63
Study 16375656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16375656 — intervention group
Group type: COMPARATOR
Intervention: Low-function controls
Number of subjects: 63
Study 16375656 — intervention group
Group type: COMPARATOR
Intervention: MCI
Number of subjects: 63
Study 16375656 — intervention group
Group type: COMPARATOR
Intervention: AD
Number of subjects: 63
Study 11927789 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 308
Study 11927789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 9616446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride (Salagen)
Number of subjects: 0
Study 9616446 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (Saliva Orthana)
Number of subjects: 0
Study 7649340 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole-D (10 mg astemizole/240 mg pseudoephedrine)
Number of subjects: 240
Study 7649340 — intervention group
Group type: COMPARATOR
Intervention: Loratadine-D (5 mg loratadine/120 mg pseudoephedrine)
Number of subjects: 240
Study 2668051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (50 g)
Number of subjects: 6
Study 2668051 — intervention group
Group type: COMPARATOR
Intervention: Glucose (50 g)
Number of subjects: 6
Study 1067352 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preventive measures including ingestion of fluoridated water (1.0 ppm), topical application of acidulated phosphate fluoride, application of a pit and fissure sealant, early detection of caries, restoration of affected teeth, and dental health education.
Number of subjects: 1200
Study 1067352 — intervention group
Group type: COMPARATOR
Intervention: Dental health education program and consumption of fluoridated water (1.0 ppm).
Number of subjects: 1200
Study 31964219 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Black Seed Oil (80 mg/kg/dose, divided into 3 doses for 1 week after each doxorubicin dose)
Number of subjects: 40
Study 31964219 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 40
Study 30641335 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief pain and smoking (BPS) cessation intervention
Number of subjects: 0
Study 28202439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse-HOMA-IR
Number of subjects: 20
Study 28202439 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA2-%S
Number of subjects: 20
Study 28202439 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 20
Study 28202439 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised-QUICKI
Number of subjects: 20
Study 28202439 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda
Number of subjects: 20
Study 28202439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutt
Number of subjects: 20
Study 28202439 — intervention group
Group type: EXPERIMENTAL
Intervention: OGIS
Number of subjects: 20
Study 25376604 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-meter walk test
Number of subjects: 136
Study 25376604 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-meter walk test
Number of subjects: 136
Study 25376604 — intervention group
Group type: EXPERIMENTAL
Intervention: First trial of 3-meter course
Number of subjects: 136
Study 25376604 — intervention group
Group type: EXPERIMENTAL
Intervention: First trial of 6-meter course
Number of subjects: 136
Study 25376604 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trial of 3-meter course
Number of subjects: 136
Study 25376604 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trial of 6-meter course
Number of subjects: 136
Study 23973701 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 6748
Study 23973701 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 6748
Study 23973701 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARBs
Number of subjects: 6748
Study 21819765 — intervention group
Group type: EXPERIMENTAL
Intervention: Microporous polysaccharide hemospheres (MPH)
Number of subjects: 40
Study 21819765 — intervention group
Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 40
Study 21819765 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH
Number of subjects: 40
Study 19317823 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose calculated for 60 g CHO
Number of subjects: 31
Study 19317823 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-g meal
Number of subjects: 31
Study 16425964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 1,280 microg (ex‐actuator, equivalent to 1,600 microg ex‐valve)
Number of subjects: 24
Study 15058128 — intervention group
Group type: COMPARATOR
Intervention: BairHugger (forced air device)
Number of subjects: 42
Study 15058128 — intervention group
Group type: EXPERIMENTAL
Intervention: SunTouch (radiant warmer)
Number of subjects: 42
Study 11336587 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 9723115 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 8
Study 9723115 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine N-oxide (CNO)
Number of subjects: 8
Study 8020524 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 300 mgI/ml at 3 ml/s
Number of subjects: 0
Study 8020524 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 200 mgI/ml at 3 ml/s
Number of subjects: 0
Study 8020524 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 300 mgI/ml at 2 ml/s
Number of subjects: 0
Study 8020524 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 200 mgI/ml at 2 ml/s
Number of subjects: 0
Study 2656071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake (50 mmol/day)
Number of subjects: 8
Study 2656071 — intervention group
Group type: COMPARATOR
Intervention: Normal salt intake (150 mmol/day)
Number of subjects: 8
Study 48773 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrhythmia computer monitoring
Number of subjects: 64
Study 48773 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring with a rate-triggered alarm system
Number of subjects: 64
Study 31916797 — intervention group
Group type: EXPERIMENTAL
Intervention: Firearm-specific lethal means safety intervention that deemphasized fear and emphasized temporariness
Number of subjects: 96
Study 31916797 — intervention group
Group type: COMPARATOR
Intervention: Other firearm-specific lethal means safety interventions
Number of subjects: 96
Study 30442323 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration (Pittsburgh Sleep Quality Index)
Number of subjects: 175
Study 30442323 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphic sleep duration
Number of subjects: 175
Study 30442323 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake after sleep onset (WASO)
Number of subjects: 175
Study 30442323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 175
Study 30442323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias in self-reporting
Number of subjects: 175
Study 28110954 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized back school program
Number of subjects: 535
Study 28110954 — intervention group
Group type: COMPARATOR
Intervention: Usual care (traditional back school)
Number of subjects: 535
Study 26767235 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block via suprainguinal approach (group S)
Number of subjects: 40
Study 26767235 — intervention group
Group type: COMPARATOR
Intervention: Fascia Iliaca Compartment Block via infrainguinal approach (group I)
Number of subjects: 40
Study 23411958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline gargle
Number of subjects: 29
Study 23411958 — intervention group
Group type: COMPARATOR
Intervention: Placebo gargle
Number of subjects: 29
Study 21467544 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-F group
Number of subjects: 201
Study 21467544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 18348137 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Kinaesthesia (JK)
Number of subjects: 20
Study 18348137 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor muscle torque
Number of subjects: 20
Study 18348137 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexor muscle torque
Number of subjects: 20
Study 18348137 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Position Sense (JPS)
Number of subjects: 20
Study 18348137 — intervention group
Group type: EXPERIMENTAL
Intervention: JK and muscle torque measurements
Number of subjects: 20
Study 18348137 — intervention group
Group type: EXPERIMENTAL
Intervention: JPS test
Number of subjects: 20
Study 16822112 — intervention group
Group type: EXPERIMENTAL
Intervention: GA referral plus 8 sessions of individual CB therapy
Number of subjects: 231
Study 16822112 — intervention group
Group type: EXPERIMENTAL
Intervention: GA referral plus a cognitive‐behavioral (CB) workbook
Number of subjects: 231
Study 16822112 — intervention group
Group type: COMPARATOR
Intervention: GA referral
Number of subjects: 231
Study 12839616 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream, applied topically three times a week
Number of subjects: 12
Study 12839616 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study 10235527 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 24
Study 10235527 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 24
Study 8886299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid mixture
Number of subjects: 40
Study 8886299 — intervention group
Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 40
Study 1698137 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylaminoethyl-dextran (3 g total) taken 30 min before a standard mixed test meal
Number of subjects: 8
Study 6163165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg to 600 mg orally for 3 months)
Number of subjects: 20
Study 6163165 — intervention group
Group type: COMPARATOR
Intervention: Conventional fibrinolytic agents only (Control)
Number of subjects: 20
Study 31226213 — intervention group
Group type: EXPERIMENTAL
Intervention: PFT-guided clopidogrel (n=755)
Number of subjects: 2527
Study 31226213 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel switched to prasugrel (n=511)
Number of subjects: 2527
Study 31226213 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel in control patients with HPR (n=188)
Number of subjects: 2527
Study 31226213 — intervention group
Group type: EXPERIMENTAL
Intervention: Low platelet reactivity (LPR)
Number of subjects: 2527
Study 27923158 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg/day rosuvastatin
Number of subjects: 61
Study 27923158 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg/day atorvastatin
Number of subjects: 61
Study 27923158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 10mg/day atorvastatin with 10mg/day ezetimibe
Number of subjects: 61
Study 25838505 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 139
Study 24449008 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (sudden perturbation)
Number of subjects: 0
Study 24449008 — intervention group
Group type: EXPERIMENTAL
Intervention: Group G (gradual perturbation)
Number of subjects: 0
Study 22824447 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAF‐T program (n = 252)
Number of subjects: 502
Study 22824447 — intervention group
Group type: COMPARATOR
Intervention: Attention control (n = 250)
Number of subjects: 502
Study 19945284 — intervention group
Group type: EXPERIMENTAL
Intervention: Clever Balance Board (CBB) test
Number of subjects: 56
Study 19945284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharpened-Romberg test
Number of subjects: 56
Study 19945284 — intervention group
Group type: EXPERIMENTAL
Intervention: Single limb stance test
Number of subjects: 56
Study 17391225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propofol (25 microg/kg per minute) and ketamine (25 microg/kg per minute)
Number of subjects: 32
Study 17391225 — intervention group
Group type: COMPARATOR
Intervention: Combination of propofol (25 microg/kg per minute) and ketamine (12.5 microg/kg per minute)
Number of subjects: 32
Study 16286279 — intervention group
Group type: EXPERIMENTAL
Intervention: Right IMA anastomosed to left coronary artery system (Group A)
Number of subjects: 94
Study 16286279 — intervention group
Group type: EXPERIMENTAL
Intervention: Right IMA anastomosed to right coronary artery system (Group B)
Number of subjects: 94
Study 16286279 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG in Group B
Number of subjects: 94
Study 16286279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency of right IMA to coronary artery system
Number of subjects: 94
Study 16286279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency of left IMA vs right IMA
Number of subjects: 94
Study 16286279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency of left and right IMA anastomosis on beating heart in Group B
Number of subjects: 94